Cargando…
Randomized dose-finding study of batefenterol via dry powder inhaler in patients with COPD
BACKGROUND: Batefenterol is a novel bifunctional muscarinic antagonist β(2)-agonist in development for COPD. The primary objective of this randomized, double-blind, placebo-controlled, active comparator, Phase IIb study was to model the dose–response of batefenterol and select a dose for Phase III d...
Autores principales: | Crim, Courtney, Watkins, Michael L, Bateman, Eric D, Feldman, Gregory J, Schenkenberger, Isabelle, Kerwin, Edward M, Crawford, Catriona, Pudi, Krishna, Ho, Shuyen, Baidoo, Charlotte, Castro-Santamaria, Ramiro |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6413745/ https://www.ncbi.nlm.nih.gov/pubmed/30880951 http://dx.doi.org/10.2147/COPD.S190603 |
Ejemplares similares
-
A randomized, controlled, repeat-dose study of batefenterol/fluticasone furoate compared with placebo in the treatment of COPD
por: Crim, Courtney, et al.
Publicado: (2020) -
Pharmacokinetics, Excretion, and Mass Balance of [(14)C]‐Batefenterol Following a Single Microtracer Intravenous Dose (Concomitant to an Inhaled Dose) or Oral Dose of Batefenterol in Healthy Men
por: Ambery, Claire, et al.
Publicado: (2018) -
In vitro dose comparison of Respimat(®) inhaler with dry powder inhalers for COPD maintenance therapy
por: Ciciliani, Anna-Maria, et al.
Publicado: (2017) -
Patients’ usability of seven most used dry-powder inhalers in COPD
por: Dal Negro, Roberto W., et al.
Publicado: (2019) -
Efficacy and safety of fluticasone furoate/vilanterol or tiotropium in subjects with COPD at cardiovascular risk
por: Covelli, Henry, et al.
Publicado: (2015)